BiotechTube
Home/MIRA Pharmaceuticals/Matthew Del Giudice
MD

Matthew Del Giudice

Director

MIRA Pharmaceuticals

Therapeutic Areas

NeurologyPsychiatry

MIRA Pharmaceuticals Pipeline

DrugIndicationPhase
Ketamir-2 (Ketamir)Neuropathic Pain (NP)Phase 1
MIRA-55Anxiety & Cognitive Decline (e.g., early-stage dementia)Preclinical

Leadership Team at MIRA Pharmaceuticals

EA
Erez Aminov
Chairman of the Board and Chief Executive Officer
NM
Ned Macpherson
Director
DN
Denil N. Shekhat
Director
IA
Itzchak Angel
Chief Scientific Advisor
View full MIRA Pharmaceuticals profile